Mati Therapeutics Inc.

Other

Forsight Labs, LLC

Forsight Vision5, Inc.

Michigan State University

Transcend Medical, Inc.

Alcon, Inc.

Twelve, Inc.

The Foundry, Inc.

Potrero Medical, Inc.

Novartis Ag

St Jude Medical, Atrial Fibrillation Division, Inc

Heartport, Inc.

Qlt Inc.

Journey1, Inc.

Stephen A Boyd

Eugene De Juan, Jr

Cary J Reich

Hanson S Gifford, Iii

Mark E Deem

Jose D Alejandro

Alan R Rapacki

David Sierra

Dan Rosenman

Douglas Sutton

Yair Alster

K Angela Macfarlane

Hanson Gifford

Daniel Rogers Burnett

Michael J Hendricksen

Darin Charles Gittings

John Anthony Scholl

Richard L Lindstrom

Vivek Shenoy

Evan Scott Luxon

Karun D Naga

Michelle M Arney

Honglei Wang

Michael Steven Feldstein

Kondapavulur T Venkateswara-Rao

Martin Williams

Koon Kiat Teu

Jingnan Luo

Tuan Anh Nguyen

Thomas J Pinnavaia

Scott Clinton Anderson

John Henry Stevens

Jonathan L Podmore

Richard L Mueller

Matthias Vaska

John William Sliwa

Philip Christopher Evard

John Edwards Crowe

William S Peters

Timothy Edward Ciciarelli

Eugene De Juan

Marcie Hamilton

Frederick G St Goar

Daniel R Burnett

Hanson S Gifford

Joseph Samuel Accetta

Rich Keenan

Janelle Chang

Alexander J Gould

Ravi Kukkadapu

Jackie Joe Hancock

Daniel Boon Lim Seet

Patrick H Ruane

Dimitri Sokolov

Christopher V Cardenas

Tommy Jewell

Lorrie Ma

Christina Skieller

Deepank Utkhede

James L Cox

Craig L Adams

Michael C Holzbaur

Alex Yee

Mark Ziegler

Saheel Sutaria

Casey Tansey

Robert W Shimizu

Rachna Jain

Drew Hoffmann

Max M Mortland

John L Palumbo

Hui Li

Cheng Gu

Hanson G Gifford, Iii

Ngoc-Tuan Nguyen

Michelle Arney

Alexander Julian Gould

Hanson S Gifford Iii

Evan S Luxon

Alan Rapacki

Angela K Macfarlane

Kondapavulur Venkateswara-rao

Griffeth Tully

Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.

Glaucoma treatment device

An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.

Nasolacrimal drainage system implants for drug therapy

An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.

Drug delivery methods, structures, and compositions for nasolacrimal system

Systems, devices and methods for draining and analyzing bodily fluids are disclosed in which a drainage assembly is configured to prevent negative pressure build-up. The drainage assembly generally includes a catheter which may include a drainage lumen, a reservoir, a venting mechanism in fluid communication with the drainage lumen and a positive pressure lumen, and a controller. The venting mechanism may further include a valve which is configured to maintain a closed position, as well as a vent in fluid communication with the valve, where the venting mechanism is configured to inhibit wetting of the vent from fluid within the drainage lumen.

Systems, devices and methods for draining and analyzing bodily fluids

The present invention provides devices and methods for decalcifying an aortic valve. The methods and devices of the present invention break up or obliterate calcific deposits in and around the aortic valve through application or removal of heat energy from the calcific deposits.

Intravascular treatment catheters

The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Implantable depots for the controlled release of therapeutic agents

This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.

Lacrimal implant detection

Devices and methods for monitoring physiologic parameters are described herein which may utilize a non-invasive respiratory monitor to detect minor variations in expiratory airflow pressure known as cardiogenic oscillations which are generated by changes in the pulmonary blood volume that correspond with the cardiac cycle. These cardiogenic oscillations are a direct indicator of cardiac function and may be used to correlate various physiologic parameters such as stroke volume, pulmonary artery pressure, etc.

Devices and methods for monitoring physiologic parameters

A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

Ocular insert apparatus and methods

A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

Anterior segment drug delivery

A knotless suture anchoring system includes an outer anchor having a central channel and a distal tip adapted to penetrate tissue. An inner anchor is positionable in the central channel of the outer anchor and a locking feature on one or both of the inner and outer anchors retains the inner anchor within the central channel. A continuous length of suture is coupled with the inner and outer suture anchors and has a free end. At least one of the inner and the outer anchors also has a cinching mechanism that allows the suture to be tensioned by passage of the suture through the cinching mechanism in a first direction while movement of the suture through the cinching mechanism in a second direction opposite the first direction is constrained.

Methods and devices to treat diseased or injured musculoskeletal tissue

Growing community of inventors

East Lansing, MI, United States of America

Stephen A Boyd